MG

Matt Gline

Things Matt Says on Podcasts

Biotech industry voice who hosts Off-Target Effects with Matt Gline, a BiotechTV interview series with investors and company leaders such as Perceptive's Joe Edelman, BridgeBio's Neil Kumar and Alnylam's John Maraganore. Joins the weekly Biotech Hangout roundtable on IPOs, drug pricing policy and clinical data, and appears as a guest on The BioCentury Show, BioBoss and The Top Line.

Where to Find Them

Matt Gline hosts Biotech Hangout and hosts Off-Target Effects with Matt Gline . They have also been a guest on BiotechTV - News (2 times) , The BioCentury Show , BioBoss and The Top Line .

Recently: “Episode 204 - November 20, 2026” on Biotech Hangout (November 2026); “Jefferies London 2026: A top biotech CEO (Roivant's Matt Gline) and top investor (Affinity Asset Advisors' Patrick Nosker) talk running biotech companies and investing in them” on BiotechTV - News (November 2026); “Episode 197 - September 25, 2026” on Biotech Hangout (September 2026); “Episode 189 - July 17, 2026” on Biotech Hangout (July 2026); “Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model” on The BioCentury Show (July 2026); “Episode 7: Perceptive Advisors' Joe Edelman discusses how biotech investing has changed over his extensive career, and his thoughts on running an investment firm” on Off-Target Effects with Matt Gline (June 2026).

What They Said

“What you want from FDA is they tell you one thing, and then you spend a bunch of money and run a trial and take all this risk. Then you get the data, go back to FDA and say, we did the thing we said we were going to do. You want the FDA that you come back to to have a consistent view with the one they had years before. Stability matters. Uncertainty is harmful.” — Matt Gline, Biotech Hangout

Reacting to the withdrawal of a nominee for FDA commissioner, Gline, who runs a drug company, explains what developers actually need from the agency. His point is that consistency across the years a trial takes matters more than any one policy.

Biotech Hangout · 2026-11-20 Permalink → Listen →
Biotech Hangout Around 15:33 into the episode
Brian Skorney

…and the Trump administration. And I don't know if anyone else has any perspectives from the industry side of things, but are we worried about sort of consistency and some sort of standardization of the FDA here? Does this make it even more uncertain how drug decisions are going to be made? Yeah,

Graig Suvannavejh

…So I do think it's going to result in a stalemate. I think it's going to, Brian, to your point, I think we're going to have a lot of uncertainty. And I hope Kyle, the fact that he's there might be the best thing we have for a protracted, lengthy confirmation process for a new FDA commissioner.

Matt Gline

My only comment on this is: as a company, what you want from FDA, the single most important thing you can get from FDA is they tell you one thing, and then you go off and you spend a bunch of money and you run a trial and you like, you hope that it works and you take all this risk. And then like you get the data and then you go back to FDA and you're like, okay, we did the thing we said we were going to do. Now, like, what next? Is you want the FDA that you come back to to have the same view, or at least a consistent view with the one they had years before. And so stability matters. Uncertainty is harmful. I'll say, like, over the last 24 months through everything that has happened politically, it's like the FDA has held it together pretty well. Like, there have been some glaring public complicated exceptions, but like mostly drugs are getting approved. Our interactions with FDA have been professional. They've been thoughtful. They've been consistent. You know, they've been technocratic in the historical sense that FDA has always been technocratic. And I think that's good. And I hope that continues. I think it was sort of interesting. I…

Graig Suvannavejh

Just one comment on the FDA functioning. This is close. I think it will be close to a record year of drug approvals. It's definitely in the top five, I think, across Cedar and Sieber. So that, I mean, for that metric, that's pretty good for our industry. I agree.

Brian Skorney

I would note something else, which is I'm personally paying a lot of attention to the Trump administration. And so, you know, we saw Stephen Miller come back as Trump's chief of staff. And so in general, I think people view him very negatively. I certainly don't have a positive view on what Trump…

Matt Gline

House cyber director with a woman named Kristen Davies, who frankly looks very qualified for the job. And like, that's an important job right now in the United States. And, you know, the news stories say that Stephen Miller was behind that. And, you know, there's a theory that maybe the second half…

Speaker names come from our own diarization. The position is estimated from where the line sits in the episode.
“I have a sneaking suspicion that the upfront components of these deals are secretly getting larger over time. It used to be people were trying to publish biobucks so as to conceal a low upfront in an overall big number. It may be that now the opposite is happening: biobucks numbers are being used by the buyer to keep quieter about the size of the upfront, to buy flexibility on their next deals.” — Matt Gline, Biotech Hangout

The hosts were complaining that headline "up to $X billion" licensing deals are too opaque to show real value. Gline offers a contrarian reading of why buyers now keep the upfront payment quiet.

Biotech Hangout · 2026-11-20 Permalink → Listen →
Biotech Hangout Around 33:19 into the episode
Graig Suvannavejh

…I think there's more opacity around when we hear these deals done. What exactly is the value that's being played? And that's true, whether it's a licensing deal or an acquisition with earnouts. You still really don't know what is going to be exchanged. So, just briefly opening that up, any comments

Tim Opler

on have you guys seen kind of an increase in the marketing of these BioBuck deals? Anyone?

Matt Gline

Can I say, I, for what it's worth, this is a tradition as old as the sun in biotech and goes back since long before I was in the industry. And I guess, like, my view, if I had to guess, is that if anything, that it used to be that people would do $10 million upfront, billion and a half dollar milestone kind of deals and call them up to a billion and a half dollars. And I'm sure that still happens. But I have a sneaking suspicion that the upfront components of these deals is secretly getting larger over time. And that if anything, that what used to be happening is that people were trying to publish BioBucks deals so as to conceal the fact that they had received a low upfront in an overall big number. And that it may be the case now that actually the opposite is happening: that BioBucks numbers and up to numbers are being used, in fact, by the buyer to keep quieter about the size of the upfront in a transaction to buy them flexibility on their next deals. Like, I can think of a BioBucks announced deal by Eli Lilly a little while ago that I had interest in, where I did some underground digging, and it seemed like potentially the upfront was very large in a way that I suspect the…

Graig Suvannavejh

Yeah, I think that's right, Matt. And again, I'm not suggesting these are low upfronts. I think it's just interesting. I, you know, whoever wants to conceal it, right? But Lilly, I mean, just to put in perspective, 30 plus billion in acquisition. That's almost a rounding error for their market cap…

Tim Opler

like their strategy of really doing a big land grab. And I mean, I don't know how they're going to manage all of it. Integrate all of this to manage that many programs. I mean, obviously, they can hire people, but hiring quality people and keeping on top of it all, I'm sure they're employing AI to…

Graig Suvannavejh

conversation in our industry has reached a fever pitch recently with the Anthropic IPO and with the isomorphic labs. But Bruce Booth posted something that got a lot of following and engagement on X, basically talking about China versus AI and almost like we have these two massive behemoths, and he…

Speaker names come from our own diarization. The position is estimated from where the line sits in the episode.
“What you can read in the Isomorphic valuation is a bet by tech people that Isomorphic is going to be among the winners in AI for biotech. But at some point these markets are going to come crashing into one another, and we're going to have to figure out how AI for biotech gets valued when the thing it's valued on is actual drugs produced and marketed to the world.” — Matt Gline, Biotech Hangout

The hosts discussed Isomorphic Labs' reported raise at a $50 billion valuation, which people had compared with established drugmakers. Gline says tech investors and biotech investors value companies on completely different bases, and that the two will eventually have to reconcile.

Biotech Hangout · 2026-11-20 Permalink → Listen →
Biotech Hangout Around 42:12 into the episode
Matt Gline

…me is like an oversimple characterization, but I just feel like being afraid of new people coming in and developing drugs faster and better. Like that's just that to me shouldn't be the tone of the industry. I guess this to me is a little bit what Bruce and Peter both, I think, have advocated for.

Graig Suvannavejh

…earlier deals in pharma. They're not afraid to go early, pull it inside. It's not a China AI versus biotech. It's a pharma versus U.S. biotech. And so that's what I'm interested to watch. I am more in the camp of free markets. It's better for us. That's the thing that I think we need to keep. Well,

Matt Gline

pharma historically has. Anyway, we'll see how pharma does with early stage drug development as time goes on. Isomorphic raised, I think, $5 billion at a $50 billion valuation. And, you know, I think isomorphic has been around a little bit, but this is obviously just an incredibly eye-popping number. And there have been a bunch of people who have like tried in various ways to create, you know, valuation comparisons to like show other whatever. You know, UCB is a 50 billion dollar Euro market cap or, you know, Reuvin's a $28 billion market company. Biogen is a $37 billion market company. You look at isomorphic and you're like, that's a big number. And it is a big number. My only, like, the thing that I think is interesting about this is I think that desire to compare as between isomorphic's valuation and biotech companies valuations, I think, like misses an important point, which is that they are just trading on completely separate and largely disjointed markets. And so like the people involved in the isomorphic financing, you know, it was led by, I think, Green Oaks and Sequoia with, you know, with people like A16Z, who obviously do some biotech…

Graig Suvannavejh

I think that's a very fair point, Matt. There's a lot of other stuff that

Matt Gline

goes on in terms of valuations that is not so visible. Yeah. But there was quite recently one of these companies in the bioelectronics space. So, you know, the best known company is Elon Musk's company, Neuralink. I don't know what the valuation is on Neuralink, but a kind of related company that's…

Tim Opler

billion dollars at $45 billion pre. So that's, you know, isomorphic's valuation is not crazy at all. I do think that the tech bio space is starting to see a lot more action. I do think that Anthropic has highlighted the potential. And I personally think that, you know, our industry might look a…

Speaker names come from our own diarization. The position is estimated from where the line sits in the episode.
“If Chinese companies or AI companies can develop better drugs, cheaper and faster than conventional US biotech companies, then conventional US biotech companies need to reinvent ourselves. The reason global pharma companies buy US biotech companies is because they have the best drugs. If we want to keep getting bought, we've got to keep developing the best drugs.” — Matt Gline, Biotech Hangout

A co-host worried that pharma may bypass small US biotechs by going straight to China and to AI-driven drug discovery. Gline answers that the only defense is to compete on quality. He also says he doubts AI will change things quickly.

Biotech Hangout · 2026-11-20 Permalink → Listen →
Biotech Hangout Around 39:59 into the episode
Matt Gline

…the biotech industry as where the drugs are being developed. And so, if the drugs are being developed by AI companies and in China, I think that's great for the biotech industry and bad for the companies that aren't developing the drugs. So, that's just like a slightly point of view that I have.

Graig Suvannavejh

…go and acquire the U.S. biotechs when so it's more of the pharma play, not what's happening in China in terms of drug discovery or licensing for biotech, which they potentially are trying to restrict. The issue is, is pharma going to not need the biotech as much if they can go direct to the source?

Matt Gline

Yeah, I guess I just think if biotech companies or AI companies can, sorry, if Chinese companies or AI companies can develop drugs, better drugs, cheaper and faster than conventional U.S. biotech companies, then I think conventional U.S. biotech companies, Reivan included, need to reinvent ourselves to take advantage of drug development pathways in China and AI. I have said other places I'm a little bit skeptical about AI revolutionizing things quickly, but I do think we owe it to all of ourselves. The reason that global pharma companies buy U.S. biotech companies is because they have the best drugs. If we want to keep getting bought, we got to keep developing the best drugs. That to me is like an oversimple characterization, but I just feel like being afraid of new people coming in and developing drugs faster and better. Like that's just that to me shouldn't be the tone of the industry. I guess this to me is a little bit what Bruce and Peter both, I think, have advocated for.

Graig Suvannavejh

Yeah. And by the way, I'm more in their camp, but what I'm saying is that we're seeing more earlier deals in pharma. They're not afraid to go early, pull it inside. It's not a China AI versus biotech. It's a pharma versus U.S. biotech. And so that's what I'm interested to watch. I am more in the…

Matt Gline

pharma historically has. Anyway, we'll see how pharma does with early stage drug development as time goes on. Isomorphic raised, I think, $5 billion at a $50 billion valuation. And, you know, I think isomorphic has been around a little bit, but this is obviously just an incredibly eye-popping…

Graig Suvannavejh

I think that's a very fair point, Matt. There's a lot of other stuff that

Speaker names come from our own diarization. The position is estimated from where the line sits in the episode.
“I feel like we're all just strapped to this AI thing. And thank God it's not my job to try and figure out where that's going, because I don't know. But I feel like 2027 is going to be defined first by the answer to the question: is there an AI bubble that bursts spectacularly?” — Matt Gline, Biotech Hangout

The hosts were asked how they see 2027 for biotech, after a co-host argued for a big M&A year. Gline says biotech's fate now hangs on whether the AI trade holds. He said it the day after the Anthropic IPO, during a sharp market pullback.

Biotech Hangout · 2026-11-20 Permalink → Listen →
Biotech Hangout Around 03:20 into the episode
Tim Opler

…is going to be a significant M ⁇ A year. We're seeing the rumors out this week, for example, that Sanofi might be doing something on Instemate. Who knows? But that's sort of exemplary of kind of what I was trying to say, which is expect a lot of M ⁇ A and that should carry up the biotech market.

Graig Suvannavejh

…about 2027, especially as we come down to the end of 2026? Do we think that it's going to be as robust of an IPO market and a biotech performance perspective? I could see M ⁇ A at a good pace. In fact, it could even increase given Tim's comments. But anyone else want to comment about 2020-27?

Matt Gline

For me, and you would ask me to make a comment about the Anthropic IPO too. I think the main thing that I find difficult to reason through is there's like a whole bunch of biotech specific dynamics. I thought Tim did a really nice job of laying it out. It feels like we are all strapped to a whatever. We're like the cartoon where like the guy catches a shark by accident on his fishing line and then the shark is like dragging him all over the lake or the ocean. I feel like we're all just like strapped to this AI thing. And it's, you know, thank God it's not my job to try and figure out where that's going because I don't know. But I feel like 2027, if I had to guess, is going to be defined first by the answer to the question, like, is there an AI bubble that bursts spectacularly? In which case, how exactly that affects biotech is difficult to predict, but it's probably not going to be fun. Or like, do we somehow sail through that moment without that, in which case it'll be better? And I feel like the capital markets first and foremost will wind up dominated by…

Brian Skorney

Yeah, let me just add to what Matt's saying, because I think he's spot on. So I did a, I was thinking the same themes and I did a quick AI search. So take it with a grain of salt. But I said, what percent of the total U.S. stock market publicly traded companies is represented by the companies that…

Tim Opler

that. I did not know that statistic. That's interesting.

Brian Skorney

Yeah. So that supports the theme that a lot of this is AI or tech. And man, we're kind of beholden to the market if those companies crater. because they are shifting their business model and they're not the cash machines that Google used to be and just printing money. That's not the case with these…

Speaker names come from our own diarization. The position is estimated from where the line sits in the episode.

Collections They Appear In